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Objectives: The estimated prevalence of complicated gastroesophageal reflux dis-
ease (GERD) is approximately 2% in the European population and showing 10-fold 
increase over the past 20 years. The objective of this paper was to find out the level 
of QoL in patients with GERD in Slovakia. MethOds: The primary method used for 
the analysis of QoL was the presence of transient disability period and combined 
questionnaire consisting of 4 parts: A. Demography and socioeconomics (13 items), 
B. Generic questionnaire (SF-36), C. Visual scale (4 items), D. Complementary (infor-
mation and habits, 13 items). The Likert scale was used in closed questions. The 
sample included 100 patients treated in the gastroenterological outpatient clinic 
(34 men and 66 women). Of these, 72 patients were in productive age. The patients 
were chosen according to the order in which they visited the clinic. Results: One 
month and two months of sick days were recorded in 8.3% and 7% of patients, 
respectively; 84,7% of patients did not report any sick days. The loss of money of 
up to 400 € and between 401 and 800 € was recorded in 11.1% and 4.2 % of patients, 
respectively; 84.3 % of did not report any loss of money. Present level of QoL was 
identified as 5.12 on the scale of 10, while in the time of the GERD diagnosis it was 
3.86. QoL was 8.25 in the time without GERD and 8.17 in optimal state of health, 
respectively. Future expectations were perceived as positive in 56% of patients and 
negative in 44% of patients. cOnclusiOns: A total of 95% of patients were well 
and very well informed about its characteristics. Paradoxically, only 48% of them 
used their medications regularly, although regular and occasional administration 
of medications was shown to have positive impact on health status in 56% and 44% 
of patients, respectively.
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Objectives: Hepatitis C virus (HCV) infection is the most common cause of liver 
cirrhosis and liver cancer worldwide. In addition to low disease awareness both in 
public and affected patients, a low disease treatment rate remains to be an impor-
tant issue regarding disease control in primary care. The nationwide prevalence 
of anti-HCV seropositivity in Taiwan is 4.4%. However, there are scattered hyper-
endemic areas in Southern Taiwan with an extremely high prevalence rate reaches 
57.9% high. Therefore, several public health strategies with periodic assessment 
aiming to promote liver health have been performed for two decades. MethOds: 
We aimed to elucidate the reasons of lower treatment rate in our country. In this 
hospital-based, physician-oriented study, a proportional sampling based on previous 
documented HCV prevalence of geographic locations in Taiwan was conducted. An 
anonymous questionnaire regarding treatment status in anti-HCV-positive patients 
was collected from these selected physicians. Patient’s information including sex, 
age, anti-HCV therapy, and the reason for not receiving antiviral therapy was 
inquired by their primary care physicians. Results: Seventy-six physicians were 
recruited into this survey (Medical center n= 46; regional hospital n= 23; primary 
clinic n= 7). A total of 2,722 anti-HCV-positive subjects in Taiwan were enrolled into 
this analysis. Among them, 54.5% (1,479/2,722) had ever received anti-HCV treat-
ment before. The treatment rate of medical centers was 63.1%, which was higher 
than 52.7% of regional hospitals, and 33.8% of primary clinics, respectively (p< 0.0001 
for pair-wise chi square test; p< 0.0001 for trend test). Males had a significantly 
higher motivation for receiving antiviral therapy than females (58.6% vs. 50.5%, 
p< 0.0001). The main reason for not receiving anti-HCV therapy was fear of side 
effects (38%), followed by ineligibility for insurance reimbursement (18%), and lack 
of awareness (11%). cOnclusiOns: In Taiwan, half of the HCV-infected patients 
have not received antiviral therapy. The low treatment rate may contribute to HCV 
hyperendemic status.
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Objectives: To conduct a systematic review of literature on factors that are 
affecting patient treatment response and risk factors for patients diagnosed 
with Non-Psychotic Major Depressive Disorder (MDD). MethOds: A literature 
search was performed using relevant search terms to identify articles published 
from 2000 to 2010 on the factors affecting treatment response and risk factors 
for MDD. Studies were identified through electronic Embase, Cochrane, Medline, 
and PubMed databases. Additional parameters were placed on the final search 
strategy to limit the retrieval to articles written in English, involving human 
subjects. Results: The initial search revealed 874 articles for factors affecting 
treatment response and 590 articles for risk factors affecting MDD from PubMed/
Medline/Embase/Cochrane databases. After removing duplicates and non-rele-
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Objectives: Direct acting antiviral therapies (DAA) in addition to PEG 2a + RBV 
(PR) are a new therapeutic option with higher rates of sustained virological 
response (SVR) than dual therapy (PR) alone in chronic hepatitis C. Currently, 
two alternatives of DAA, telaprevir (TVR) and boceprevir (BOC), are available in 
Chile. The aim of this study was to evaluate the cost-effectiveness of adding TVR 
to PR in treatment naive and previously treated patients with HCV in Chile com-
pared to PR alone and with the addition of BOC. MethOds: A lifetime Markov 
model was developed including HCV, cirrhosis, liver transplant and death as 
health states. QALYs as an outcome measure, a health care system perspective 
and a 6% discount rate for health benefits and costs have been used. Costs are 
expressed in local currency. A review of the literature to obtain epidemiologic 
and resources utilization data was performed and when data were not avail-
able or validation was needed a Delphi panel with local experts was carried out. 
Deterministic and probabilistic sensitivity analysis was performed. Results: 
In comparison with PR, TVR avoided 174 cirrhosis cases and 16 deaths per 1,000 
patients and shown an ICER of $14,730,736/QALY and $8,300,511/QALY for the 
naïve and for the previously treated patients respectively. TVR dominated BOC 
in naïve patients and in most of the previously treated ones (was less costly 
and more efficacious), except in the partial responders subgroup. Against the 
WHO criteria TVP versus PR presented 80% of probability of being cost effective 
for naïve and 96% of probability of being cost effective for previously treated 
patients. cOnclusiOns: TVR dominated BOC and was cost-effective against 
WHO 3x GDP criteria in comparison to double therapy from the national health 
care system perspective in Chile.
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Objectives: DAA treatments in addition to Ribavirin (RBV) and peginterferon 
(Peg-INF) (PR), provides the greatest opportunity to fully achieve sustained viro-
logical response (SVR) in HCV infected patients. Currently, two alternatives of 
DAA, telaprevir (TVR) and boceprevir (BOC), are available in Peru. The objective 
of this study is to assess: which is the most efficient DAA treatment to compli-
ment the PR in previously treated patients. MethOds: A Markov model was 
used from the payer perspective to estimate costs and benefits throughout the 
whole life. Transition probabilities, utilities and resources usage were obtained 
from literature and through a mixed treatment comparison. Only direct costs 
were considered as medications, laboratory tests, complications costs and 
adverse events by using tariffs and tender prices from EsSalud. Outcomes were 
measured as SVR, quality adjusted life years (QALY) and events of cirrhosis per 
1,000 treated patients. Two alternatives were assessed: 1) 12 weeks of TVR plus 
PR and 2) 24-44 weeks of BOC plus PR. Discount rate 3% and exchange rate (1 
USD = 2,6 S/). Results: 1) Total costs (USD): TVR plus PR ($56,058), BOC plus PR 
($64,536). 2) Medication costs (USD): TVR plus PR ($47,297), BOC plus PR ($54,649). 
3) SVR: TVR plus PR (76%), BOC plus PR (60%). 4) QALY: TVR plus PR (6,02), BOC 
plus PR (5,87). 5) Cirrhosis per 1,000 treated patients: TVR plus PR (311), BOC plus 
PR (363). Incremental Cost Effectiveness Ratio (ICER) was negative, showing that 
12 weeks of TVR plus PR is a dominant therapy. cOnclusiOns: When a DAA is 
considered, in addition to PR, for previously treated patients, TVR is the preferred 
choice because of its potential cost-savings versus BOC and incremental health 
benefits versus BOC.
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Objectives: Direct acting antiviral therapies (DAA) in addition to PEG 2a + 
RBV (PR) are a new therapeutic option with higher rates of sustained virologi-
cal response (SVR) than dual therapy (PR) alone in chronic hepatitis C (HCV). 
Currently, two alternatives of DAA, telaprevir (TVR) and boceprevir (BOC), 
are available in Colombia. The aim of this study was to evaluate the cost-
effectiveness of adding TVR to PR in treatment naive and previously treated 
patients with HCV in Colombia compared to PR alone and with the addition 
of BOC. MethOds: A lifetime Markov model was developed including HCV, 
cirrhosis, liver transplant and death as health states. QALYs as an outcome 
measure, a health care system perspective and a 3% discount rate for health 
benefits and costs have been used. Costs are expressed in local currency. A 
review of the literature to obtain epidemiologic and resources utilization data 
was performed and when data were not available or validation was needed a 
Delphi panel with local experts was carried out. Deterministic and probabilis-
tic sensitivity analysis was performed. Results: In comparison with PR, TVR 
avoided 172 cirrhosis cases and 24 deaths per 1,000 patients and shown an ICER 
of $21,260,647/QALY and $8,461,107/QALY for the naïve and for the previously 
treated patients respectively. TVR dominated BOC in naïve patients and in most 
of the previously treated ones (was less costly and more efficacious), except 
in the partial responders subgroup. These results were robust in the sensitiv-
ity analysis. cOnclusiOns: TVR dominated BOC and and was cost-effective 
against WHO 3x GDP criteria in comparison to PR from the national health care 
system perspective in Colombia.
